Amit N. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amit N. Patel has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
Eulsoon Park
Center for Cardiac Cell Therapy-Heart Lung Esophageal Surgical Institute, University of Pittsburgh/UPMC/McGowan Institute of Regenerative Medicine, Pittsburgh, PA, USA
2 shared publicationsFederico Benetti
Benetti Foundation, Rosario, Argentina
2 shared publicationsMichael Kuzman
Center for Cardiac Cell Therapy-Heart Lung Esophageal Surgical Institute, University of Pittsburgh/UPMC/McGowan Institute of Regenerative Medicine, Pittsburgh, PA, USA
2 shared publicationsA. Marc Gillinov
1 shared publication- Abeel A. Mangi
Section of Cardiac Surgery, Yale University School of Medicine, New Haven, Connecticut
1 shared publication - Aditya Krishna Kaza
Department of Cardiac Surgery, Boston Children's Hospital, Boston, Massachusetts.; Department of Surgery, Harvard Medical School, Boston, Massachusetts.
1 shared publication
Latest Publications
- 1 January 2010
- Published by Elsevier
Contributors
- Open Access
- 1 March 2008
- Published by SAGE Publications in Cell Transplantation
- Vol. 17 (3) , 303-311
Multipotent Menstrual Blood Stromal Stem Cells: Isolation, Characterization, and Differentiation
The stromal stem cell fraction of many tissues and organs has demonstrated to exhibit stem cell properties such as the capability of self-renewal and multipotency, allowing for multilineage differentiation. In this study, we characterize a population of stromal stem cells derived from menstrual blood (MenSCs). We demonstrate that MenSCs are easily expandable to clinical relevance and express multipotent markers such as Oct-4, SSEA-4, and c-kit at the molecular and cellular level. Moreover, we demonstrate the multipotency of MenSCs by directionally differentiating MenSCs into chondrogenic, adipogenic, osteogenic, neurogenic, and cardiogenic cell lineages. These studies demonstrate the plasticity of MenSCs for potential research in regenerative medicine.
- 1 March 2008
- Published by SAGE Publications in Cell Transplantation
- Vol. 17 (3) , 303-311
Open AccessMultipotent Menstrual Blood Stromal Stem Cells: Isolation, Characterization, and Differentiation
The stromal stem cell fraction of many tissues and organs has demonstrated to exhibit stem cell properties such as the capability of self-renewal and multipotency, allowing for multilineage differentiation. In this study, we characterize a population of stromal stem cells derived from menstrual blood (MenSCs). We demonstrate that MenSCs are easily expandable to clinical relevance and express multipotent markers such as Oct-4, SSEA-4, and c-kit at the molecular and cellular level. Moreover, we demonstrate the multipotency of MenSCs by directionally differentiating MenSCs into chondrogenic, adipogenic, osteogenic, neurogenic, and cardiogenic cell lineages. These studies demonstrate the plasticity of MenSCs for potential research in regenerative medicine.
- Open Access
- 1 October 2007
- Published by SAGE Publications in Cell Transplantation
- Vol. 16 (9) , 875-878
Cardiac Stem Cell Therapy from Bench to Bedside
- 1 October 2007
- Published by SAGE Publications in Cell Transplantation
- Vol. 16 (9) , 875-878
Open AccessCardiac Stem Cell Therapy from Bench to Bedside
- Open Access
- 1 October 2007
- Published by SAGE Publications in Cell Transplantation
- Vol. 16 (9) , 899-905
Improved Cell Survival in Infarcted Myocardium Using a Novel Combination Transmyocardial Laser and Cell Delivery System
Stem cell therapy has been used to treat ischemic cardiac disease with promising early results. However, there has been limited success using cell therapy in infarcted tissue. The cells have an inadequate microvascular environment in order to survive once implanted into scar tissue. The goal of this study was to create a microvascular environment into infarcted myocardial tissue using transmyocardial laser revascularization (TMR) as a pretreatment before cell implantation and evaluate cell survival afterwards. Balloon occlusion catheter-based myocardial infarct of the circumflex artery was created in a porcine model. The infarct was allowed to mature for 2 weeks. Three groups consisting of TMR alone (TMR), TMR + fluorescent-labeled allogeneic mesenchymal stem cells (MSCs) (TMR + Cells), and MSCs alone (Cells) were injected into the infarcted tissue using a combination TMR and cell delivery system (Phoenix™, Cardiogenesis). The hearts were explanted at 1 week after treatment for cell and tissue evaluation. The myocardial infarcts were verified in all animals using both ultrasound and direct visual imaging. All arms of the study were successful with a mean of 2.0 ± 106 MSCs injected per site into the scar tissue. All animals survived to explant at 1 week. On histological examination, 300 high-power fields were evaluated demonstrating that the TMR + Cells group had 25 ± 5 cells and the Cells group 5 ± 2 cells compared to baseline TMR alone by fluorescence. The use of TMR as a pretreatment for MSC injection increases early cell survival in infarcted tissue without increased adverse events. Further long-term functional and differentiation analysis will be required to evaluate the efficacy for future clinical translation.
- 1 October 2007
- Published by SAGE Publications in Cell Transplantation
- Vol. 16 (9) , 899-905
Open AccessImproved Cell Survival in Infarcted Myocardium Using a Novel Combination Transmyocardial Laser and Cell Delivery System
Stem cell therapy has been used to treat ischemic cardiac disease with promising early results. However, there has been limited success using cell therapy in infarcted tissue. The cells have an inadequate microvascular environment in order to survive once implanted into scar tissue. The goal of this study was to create a microvascular environment into infarcted myocardial tissue using transmyocardial laser revascularization (TMR) as a pretreatment before cell implantation and evaluate cell survival afterwards. Balloon occlusion catheter-based myocardial infarct of the circumflex artery was created in a porcine model. The infarct was allowed to mature for 2 weeks. Three groups consisting of TMR alone (TMR), TMR + fluorescent-labeled allogeneic mesenchymal stem cells (MSCs) (TMR + Cells), and MSCs alone (Cells) were injected into the infarcted tissue using a combination TMR and cell delivery system (Phoenix™, Cardiogenesis). The hearts were explanted at 1 week after treatment for cell and tissue evaluation. The myocardial infarcts were verified in all animals using both ultrasound and direct visual imaging. All arms of the study were successful with a mean of 2.0 ± 106 MSCs injected per site into the scar tissue. All animals survived to explant at 1 week. On histological examination, 300 high-power fields were evaluated demonstrating that the TMR + Cells group had 25 ± 5 cells and the Cells group 5 ± 2 cells compared to baseline TMR alone by fluorescence. The use of TMR as a pretreatment for MSC injection increases early cell survival in infarcted tissue without increased adverse events. Further long-term functional and differentiation analysis will be required to evaluate the efficacy for future clinical translation.
- 1 September 2007
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 22 (5) , 464-470
Stem cell therapy for the treatment of heart failure
Congestive heart failure is a complex clinical syndrome resulting from myocardial dysfunction that impairs the cardiovascular system's function. Medical and surgical therapy both still result in a large number of patients with very few options and persistent ventricular dysfunction. The major process to reverse ventricular remodeling would be the enhancement of regeneration of cardiac myocytes, as well as the stimulation of neovascularization within the affected area of the myocardium. This can be achieved by introducing progenitor cells that are capable of differentiating into cardiac myocytes, or that promote neovascularization and restore the normal characteristics of myocardium environment. A number of issues remain as to the type of cells, delivery, timing, and mechanisms involved, however. There have been a number of clinical trials in patients with heart failure that have been based on animal data related to stem cell therapy. Most have utilized whole bone marrow cells or myoblasts. The majority of the studies demonstrate an improvement in ventricular function, reduction in scarring, and improvement in symptoms. Some trials have shown no improvement at all. This review examines the bench-to-bedside developments of stem cell therapy related to congestive heart failure.
- 1 September 2007
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 22 (5) , 464-470
Stem cell therapy for the treatment of heart failure
Congestive heart failure is a complex clinical syndrome resulting from myocardial dysfunction that impairs the cardiovascular system's function. Medical and surgical therapy both still result in a large number of patients with very few options and persistent ventricular dysfunction. The major process to reverse ventricular remodeling would be the enhancement of regeneration of cardiac myocytes, as well as the stimulation of neovascularization within the affected area of the myocardium. This can be achieved by introducing progenitor cells that are capable of differentiating into cardiac myocytes, or that promote neovascularization and restore the normal characteristics of myocardium environment. A number of issues remain as to the type of cells, delivery, timing, and mechanisms involved, however. There have been a number of clinical trials in patients with heart failure that have been based on animal data related to stem cell therapy. Most have utilized whole bone marrow cells or myoblasts. The majority of the studies demonstrate an improvement in ventricular function, reduction in scarring, and improvement in symptoms. Some trials have shown no improvement at all. This review examines the bench-to-bedside developments of stem cell therapy related to congestive heart failure.
- 1 December 2005
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 130 (6) , 1631-1638.e2
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study
- 1 December 2005
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 130 (6) , 1631-1638.e2
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study